Reversing Lp(a) and CV Risk: Antisense Oligonucleotides - FORD BREWER MD MPH

from Dr Ford Brewer - PrevMed · host Dr. Ford Brewer

For more information, contact us at 859-721-1414 or [email protected]. Also, check out the following resources: ·Newsletter Sign Up·Jubilee website·PrevMed's website·PrevMed's Rumble channel·PrevMed's YouTube channel·PrevMed's Facebook page·PrevMed's Instagram·PrevMed's LinkedIn·PrevMed's Twitter ·PrevMed's Pinterest

Episode metadata supplied by the publisher feed · Published Sep 27, 2022

Embed this episode

Attribution link and audio player

What this episode covers

Recently published in NEJM (New England Journal of Medicine) is an article about antisense oligonucleotides. It's a new drug that reduces Lp(a) or lipoprotein (a) by up to 80%. This is more promising than current treatments, including niacin, L-carnitine, and apheresis. Still, the new antisense drug appears to be not yet ready for primetime. Here's the link to the NEJM article: https://www.nejm.org/doi/full/10.1056/NEJMoa1905239

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Reversing Lp(a) and CV Risk: Antisense Oligonucleotides - FORD BREWER MD MPH

0:00 10:54

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Dr Ford Brewer - PrevMed?

This episode is 10 minutes long.

When was this Dr Ford Brewer - PrevMed episode published?

This episode was published on September 27, 2022.

Can I download this Dr Ford Brewer - PrevMed episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!